Osteogenesis imperfecta (OI), also known as brittle bone disease, is a rare genetic disease affecting the connective tissue and bones. In this disease, bones become extremely fragile and break or ...

Mereo Biopharma ( (MREO) ) has released its Q3 earnings. Here is a breakdown of the information Mereo Biopharma presented to its investors.

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on MREO stock, giving a Buy rating on November 12. Joseph ...

Everyone remembers Atticus as the quirky Brick Heck from The Middle, when he was just 11 years old. Over the nine seasons the ...

I would suggest investors take a close look at setrusumab for osteogenesis imperfecta (OI). The program is in late-stage ...

The writers have been pulling at our heartstrings for two decades now, but sometimes, they just rip our hearts into shreds ...

You have full access to this article via your institution. In human JEB, besides mutations of the laminin-5 gene, mutations in type XVII collagen and α6β4-integrin genes have been reported 25.

THE parents of 12-year-old Ramona-Shae Thorpe, who was denied access to public education due to her brittle bone disorder, ...

The clichéd view obviously being that if she is attending an expensive school she doesn’t need State help. Apparently, ...

Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ...

A fundraising appeal for a child born with a rare condition that makes her bones brittle has reached its £10,000 target. Natarlia was born in May 2022 with osteogenesis imperfecta. In September ...

KDEV) today announces that its portfolio company BOOST Pharma has succesfully completed a pre-IND meeting with the U.S. Food and Drug Administration, FDA, for its cell therapy aiming to treat children ...